News

The study, designed to evaluate the safety and efficacy of the once-daily dopamine agonist rotigotine, found that the drug significantly improved symptoms in the patients taking part versus

Applications of the ddRNAi technology for research activities have been licensed exclusively by Sigma- Aldrich from Benitec Limited of Australia. Financial details of the deal were not disclosed.

Scientists at Yale School of Medicine have reported that estrogen is a strong regulator of energy metabolism through the brain, after studying mice with mutations in leptin or

The antibody product, IMC-3G3, was developed using Medarex’s UltiMAb technology and is the second UltiMAb-derived antibody in clinical development by ImClone Systems. US-based Medarex said that the company

Picoplatin, the company’s lead product candidate, is a new generation platinum therapy with an improved safety profile. It is designed to overcome and prevent platinum resistance associated with

The Byetta injection will be used specifically for those diabetes patients who have not achieved adequate control on a thiazolidinedione (TZD). In a trial designed to evaluate Byetta

Pending authorization, the phase I/IIa clinical trial of Neugranin will be a safety and tolerability trial in patients with breast cancer. In the first phase of the study,

The phase IIa trial was designed to assess the safety and efficacy of a 28-day treatment course of inhaled Aerovant. The study met its primary endpoint of reducing

Beta-blockers help to reduce the heart’s workload via their action on beta-adrenergic receptors present in cardiac cells. The single amino acid change in the beta1-adrenergic receptor may differ